Article
Original Article

Paul Richards M1*, Madankumar2 , Nandan kumar3 , N Sharath Gowda4 , K Khairat5 , Prajwal R Shankar6

Aditya Bangalore Institute of Pharmacy Education and Research, Kogilu, Yelahanka, Bangalore-64.

*Corresponding author:

Dr. Paul Richards M, Professor & HOD, Aditya Bangalore Institute of Pharmacy Education and Research, Department of Pharmaceutical Analysis and QA. E-mail: richie2626@gmail.com Affiliated to Rajiv Gandhi University of Health Sciences, Bengaluru, Karnataka.

Received date: January 5, 2022; Accepted date: March 9, 2022; Published date: March 31, 2022

Received Date: 2022-01-05,
Accepted Date: 2022-03-09,
Published Date: 2022-03-31
Year: 2022, Volume: 12, Issue: 1, Page no. 18-22, DOI: 10.26463/rjps.12_1_2
Views: 1113, Downloads: 69
Licensing Information:
CC BY NC 4.0 ICON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0.
Abstract

Azelnidipine is a ca2+ channel blocker used for treatment of patients with hypertension. The main objective was to develop UltraViolet- visible spectroscopy method for Azelnidipine which should be fast, error-free, exact, sensitive and validate the processed method according to ICH guidelines by use of API and tablet formulations of Azelnidipine by UV-visible spectroscopy. UV-visible Spectrophotometric resolution was carried out with Thermo scientific GENESYS 10S single beam spectrophotometer. A simple, rapid, precise, accurate and sensitive UV-visible Spectroscopy method has been developed for the determination of Azelnidipine by using acetone as a medium. The spectrum of the standard solution was run from 200-400 nm range for the determination of λmax and λmax of Azelnidipine was found at 255 nm. Different validation parameters such as Linearity, Accuracy, Precision, LOD and LOQ, and Robustness and various Quality Control tests like here evaluated as per ICH guidelines. Linearity for the UV-visible Spectroscopy was noted in the concentration range of 2-14µg/ml and mean correlation coefficient of 0.9993. Accuracy was found to be 98%- 100%. The precision demonstrates as relative standard deviation of Intraday and Interday which was 1.058%-1.029% and 1.144%-1.316% with %RSD less than 2 and the limit of detection which was (LOD) and limit of Quantitation (LOQ) for Azelnidipine was found to be 2.086 and 8.68 microgm/ml respectively. The proposed UV-visible spectroscopy method and its validation according to the ICH guidelines shown that method is sensitive, precise, accurate and simple for the estimation of Azelnidipine API and tablet formulation.

<p>Azelnidipine is a ca2+ channel blocker used for treatment of patients with hypertension. The main objective was to develop UltraViolet- visible spectroscopy method for Azelnidipine which should be fast, error-free, exact, sensitive and validate the processed method according to ICH guidelines by use of API and tablet formulations of Azelnidipine by UV-visible spectroscopy. UV-visible Spectrophotometric resolution was carried out with Thermo scientific GENESYS 10S single beam spectrophotometer. A simple, rapid, precise, accurate and sensitive UV-visible Spectroscopy method has been developed for the determination of Azelnidipine by using acetone as a medium. The spectrum of the standard solution was run from 200-400 nm range for the determination of &lambda;max and &lambda;max of Azelnidipine was found at 255 nm. Different validation parameters such as Linearity, Accuracy, Precision, LOD and LOQ, and Robustness and various Quality Control tests like here evaluated as per ICH guidelines. Linearity for the UV-visible Spectroscopy was noted in the concentration range of 2-14&micro;g/ml and mean correlation coefficient of 0.9993. Accuracy was found to be 98%- 100%. The precision demonstrates as relative standard deviation of Intraday and Interday which was 1.058%-1.029% and 1.144%-1.316% with %RSD less than 2 and the limit of detection which was (LOD) and limit of Quantitation (LOQ) for Azelnidipine was found to be 2.086 and 8.68 microgm/ml respectively. The proposed UV-visible spectroscopy method and its validation according to the ICH guidelines shown that method is sensitive, precise, accurate and simple for the estimation of Azelnidipine API and tablet formulation.</p>
Keywords
Azelnidipine, UV-Visible, Method validation by UV-Visible Spectroscopy, Lamda max at 255 nm.
Downloads
  • 1
    FullTextPDF
Article

Introduction

Azelnidipine (AZEL) is chemically (±)-3- (1-diphenyl methylazetidin3- yl) 5-isopropy12-amino-1, 4-dihydro6-methyl-4-(3-nitrophenyl) 3,5- pyridinedi carboxylate (Figure 1) and is a ca2+ channel blocker used to treat HT blood pressure.1 Due to an unbalanced carbon at the 4-position of 1,4 dihydropyridine ring, it appears as two enantiomers. The drug has renoprotective effects, as well as anti-atherosclerotic effects. Azelnidipine inhibits trans membrane Ca+2 influx into cell and its membrane, lowers PVR and arterial pressure through the voltage dependent medium of smooth muscle in vascular walls.2-4

Materials and Method Instrumentation:

A Thermo scientific GENESYS 10S UV-Visible spectrophotometer with 1.0-centimetre matching quartz cells were used for absorbance measurements. The UV spectrum was captured over the wavelength 200‐400 nm.5-6

Chemicals and reagents:

16 mg of AZEL (Azovas) was obtained from Apollo pharmaceuticals. The sample of azelnidipine was moderately dissolved in methanol, freely dissolved in acetone, soluble in ethyl acetate and sparingly dissolved in water.7

Preparation of standard stock solution:

A 100 milligram of Azel standard was weighed exactly and shifted to a 100 mL volumetric flask and solubilized in diluents to give a solution containing 1000 microgram/ millilitre standard stock solution of Azel.8-9

Preparation of working standard stock solution:

10 millilitre of standard stock solution was retrieved and transferred to 100 millilitre volumetric flask. Capacity was made up to the mark with diluents to get the working standard solution of 100 microgram/millilitre.10

Preparation of calibration curve of AZEL:

Suitable volumes of liquids 2, 4, 6, 8, 10, 12 and 14 microgram/ millilitre for linearity from Azel stock solutions were tranferred to distinct volumetric flasks of 10 millilitre capacity.11-12 The magnitude was adjusted to the mark with diluents to obtain concentration of 2-14 µg/mL. The absorbance of the solutions was measured at 257 nm. The calibration curve was constructed by plotting absorbance versus concentration of the drug and regression equations were determined.13

Method Validation

The process was validated to assess the reliability of outcome of the analysis for different parameters like Linearity, Range, Accuracy, Precision, Limit of detection (LOD), Limit of quantification (LOQ), and system suitability parameters of Specificity and Robustness.14-15

Linearity

Linearity was estimated by analysing the absorbance of acetone as blank standard concentration (2-14 µg/mL) at a wavelength of 257 nm.16 The calibration curve was plotted using concentration against absorbance.17-18 Ar2 equation and correlation coefficient were estimated for Azel standard concentrations (2-14 μg/mL) which is shown in Table 1.

Range

The data retrieved from the linearity and accuracy studies was used to assess the range of the method.

Accuracy

Accuracy was established by producing three samples of the solution 50, 100 and 150% of working standard and adding known concentrations of Azel to each sample solution and solubilized in 10 mL of volumetric flask with analytical grade Acetone. Accuracy was evaluated using a minimum of nine determinations over a minimum of three concentration levels for each sample.19 Absorbance values at a wavelength of 257 nm and the calculated % RSD is shown in Table 2

Precision

The instrument precision was evaluated by determining the absorbance of the standard solution of AZEL six times repeatedly.20-21 The results are reported in terms of relative standard deviation. The intra- and inter-day difference for the estimation of AZEL was carried out in triplicate for the standard solution and is shown in Table 3 and 4. 

Limit of Detection (LOD)

The identification limit of an independent analytical procedure is the lowest amount of analyte in a sample which can be identified but not definitely quantified as an exact value. The LOD was determined from the set of five calibration curves used to estimate method linearity. LOD was calculated as follows from the formula24-

LOD= (3.3*SD)/slope

Where, SD = the standard deviation of y-intercept of five calibration curves

Slope = the mean slope of five calibration curves as shown in Table 5

Limit of Quantification (LOQ)

The Quantitation limit is a parameter of quantitative assays for low levels of compounds in sample. The LOQ was evaluated from the set of five calibration curves used to estimate method linearity as shown in Table 5.

The LOQ may be calculated as LOQ = 10 × (SD/S)

Where, σ = Standard deviation of the Y- intercepts of the five calibration curves. 

S = Mean slope of the five calibration curves.

Specificity

In Ultraviolet-Visible spectroscopy, specificity was established by examining of each Azel standard solution (1-14 μg/mL) in range of 200-800 nm against acetone as blank (Figure 2).

Robustness

The results remain unaffected by slight, but deliberate differences in method parameters, change in wavelength, analysis by person to person and changing room temperature. 

Absorbance of any one concentration was measured at  three different wavelengths i.e. 254, 257, 260 nanometres and mean and % RSD were calculated.

Consent and ethical approval

It is not applicable Competing interest Writers have announced that no competing interests exists.

Supporting Files
References

1. Malairajan et al., World Journal of Pharmaceutical Research, DOI: Vol 10, Issue 10, 202110.20959/ wjpr202110-21174.

2. Chandra sekhar et al., World Journal of Pharmacy and Pharmaceutical Sciences, DOI: Vol 10, Issue 3, 202110.20959/wjpps20213-18460.

3. Raskapur et al. Int J Pharm PharmSci, International Journal of Pharmacy and Pharmaceutical Sciences, Vol 4, Issue 1, 238-240 September 2011.

4. Nagarajan et al. ejbps, European Journal of Biomedical and Pharmaceutical Sciences 2021, Volume 8, Issue 6, 272-278.

5. Kajal Patel. “In Depth Investigation of Analytical Methods for the Determination of Azelnidipine in Biological Fluid and Pharmaceutical Dosage Forms: A Review”. Acta Scientific Biotechnology 1.4 (2020): 13-17.

6. Kuramoto et al. Hypertens Res, Azelnidipine and Amlodipine: 24-h BP Effects and PK, Vol. 26, No. 3 (2003) Original Article.

7. Maji et al. Int J App Pharm, , International Journal of Applied PharmaceuticsVol 13, Issue 4, 2021, 154-159.

8. Wrasse-Sangoi et al. Quim. Nova, ,Artigo, Departamento de Farmácia Industrial, Universidade Federal de Santa Maria, Vol. 33, No. 6, 1330-1334, 201097105-900 Santa Maria - RS, Brasil.

9. International Journal of Multidisciplinary Research and Development Online ISSN: 2349-4182, Print ISSN: 2349-5979; Impact Factor: RJIF 5.72, Volume 7; Issue 1; January 2020; Page No. 20-24.

10. S. ANGALAPARAMESWARI, ISSN: 0973-4945; CODEN ECJHAO E-Journal of Chemistry http:// www.ejchem.net 2012, 9(4), 2068-2073.

11. Bhagwat et al., World Journal of Pharmaceutical Research-april 2017, ISSN 2277– 7105, Vol 6, Issue 04, 2017 DOI: 10.20959/wjpr20174-8136.

12. Ikmeet Kaur Grewal et al. Plant Archives pp. 3265- 3270 e-ISSN:2581-6063 Vol. 20 Supplement 1, 2020 (online), ISSN:0972-5210.

13. Behera S, Ghanty S, Ahmad F, Santra S, Banerjee S (2012) UV-Visible Spectrophotometric Method Development and Validation of Assay of Paracetamol Tablet Formulation. J Anal Bioanal Techniques 3:151. doi:10.4172/2155-9872.1000151.

14. The Pharma Innovation Journal, ISSN (E): 2277- 7695 ISSN (P): 2349-8242 NAAS 2019; 8(4): 30-34 Rating: 5.03 TPI 2019; 8(4): 30-34.

15. Hindawi Publishing Corporation Journal of Spectroscopy Volume 2013, Article ID 146580, 6 pages http://dx.doi.org/10.1155/2013/146580.

16. Sudhir et al.,   Oriental Journal of Chemistry · March 2013, ISSN: 0970-020 X, Orient. J. Chem., Vol. 29(1), 235-240 (2013), DOI: 10.13005/ojc/290137.

17. Raveendra Babu Ganduri et al. / International Journal of Pharma Sciences and Research (IJPSR)- June 2014, ISSN: 0975-9492, Vol 5 No 06 Jun 2014.

18. Chen et al, www.dovepress.com, https://doi. org/10.2147/TCRM.S64288, Therapeutics and Clinical Risk Management 2015:11 309–318.

19. Jayvadan K. PATEL,Nilam K. PATEL, Scientia Pharmaceutica, Sci Pharm. 2014; 82: 541–554 doi:10.3797/scipharm.1312-14.

20. Konam and Kanala, BEPLS, Bulletin of Environment, Pharmacology and Life Sciences, Vol 10 [2] January 2021: 19-27Online ISSN 2277-1808, ORIGINAL ARTICLE.

21. D. Prabhakar et al /International Journal of ChemTechResearch, CODEN (USA): IJCRGG, ISSN: 0974-4290, Vol.11 No.01, pp 07-12, 2018.

22. Xiaoxia Ye, Xu Xu / Journal of Chinese Pharmaceutical Sciences 21 (2012) 468–471, http:// www.jcps.ac.cn, DOI: 10.5246/jcps.2012.05.061, Article ID: 1003–1057(2012)5–468–04.

23. Verma et al. Int J App Pharm, , International Journal of Applied Pharmaceutics, DOI: Vol 9, Issue 5, 2017, 102-108http://dx.doi.org/10.22159/ ijap.2017v9i5.20467.

24. Pharmaceutics 2020, 12, 150; doi:10.3390/ pharmaceutics12020150, http://www.mdpi.com/ journal/pharmaceutics, 

We use and utilize cookies and other similar technologies necessary to understand, optimize, and improve visitor's experience in our site. By continuing to use our site you agree to our Cookies, Privacy and Terms of Use Policies.